Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. 1982

D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson

A randomized prospective comparison of treatment with cyclophosphamide and that with cyclophosphamide and cisplatinum, each in 21 patients with advanced ovarian cancer, has shown that the time to progression of tumor and the duration of survival were markedly improved in the patients receiving the combination chemotherapy. Cytoreductive surgery was performed in most of the patients in the study before the chemotherapy regimen was initiated. Second-look surgery was performed after a year of chemotherapy. The chemotherapy was administered on an outpatient basis, without excessive toxicity. At 2 years, 52.4% of the patients receiving combination therapy had no progression of tumor, whereas 9.5% had no progression of tumor inthe group of patients receiving a single alkylating agent. Survival at 2 years was 61.9% for the combination chemotherapy group and 19.0% for those treated with cyclophosphamide alone. The study demonstrates a striking superiority of combination chemotherapy over single-agent chemotherapy in patients with advanced ovarian cancer.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
January 1982, Clinical and experimental obstetrics & gynecology,
D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
January 1988, Jugoslavenska ginekologija i perinatologija,
D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
February 1990, Gynecologic oncology,
D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
August 1994, Gynecologic oncology,
D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
November 1985, Cancer treatment reports,
D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
January 1982, Bulletin du cancer,
D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
March 1995, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
September 1984, British journal of obstetrics and gynaecology,
D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
January 1982, Oncology,
D G Decker, and T R Fleming, and G D Malkasian, and M J Webb, and J A Jeffries, and J H Edmonson
August 1983, Tumori,
Copied contents to your clipboard!